Avita Medical (RCEL) Upgraded to Buy: Here's Why
Avita Medical (RCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Avita Medical (RCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
First U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surgery patients Findings presented at the British Burn Association Annual Meeting support the role of RECELL GO in standardizing preparation of RECELL® Spray-On Skin™ Cells and improving operating room workflow RECELL GO is CE-marked in Europe and the U.K. and recently received regulatory authorization in Australia and New Zealand VALENCIA, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the presentation of new clinical data highlighting the first documented use of RECELL GO in the United Kingdom (U.K.) at the 2026 British Burn Association (BBA) Annual Meeting in Nottingham, U.K. The presentation, titled “First U.K. Clinical Experience of RECELL GO, an Automated Autologous Cell Harvesting Device, in Burn Surgery: A Case Series,” reports outcomes from 17 patients treated at Stoke Mandeville Hospital, one of the U.K.'s leading specialist burn units.
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Prepared Remarks Transcript
AVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth Transcript
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.m.
VALENCIA, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.
Avita Medical NASDAQ: RCEL reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook as management said reimbursement conditions for its RECELL product are normalizing and demand patterns are becoming more consistent.
AVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call Transcript
VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the first quarter ended March 31, 2026.
Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately.
RECELL GO® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both markets RECELL GO is AVITA Medical's next-generation system that automates and standardizes the preparation of RECELL ® Spray-On Skin™ for the treatment of burn and trauma wounds VALENCIA, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that RECELL GO, its next-generation system for preparing RECELL Spray-On Skin, has received certification from Australia's Therapeutic Goods Administration (“TGA”) and has been listed on New Zealand's Web Assisted Notification of Devices (“WAND”) database by Medsafe, enabling commercialization in both markets for burn and acute wound treatment.
VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026.
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical Inc. (“AVITA Medical” or the “Company”) (NASDAQ: RCEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
Recognition highlights pioneering contributions to modern burn care including development of RECELL ® Spray-On Skin™ VALENCIA, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its founder, Professor Fiona Wood, has been awarded the Lifetime Achievement Award by the American Burn Association (ABA).
Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cohealyx interim data show ~20-day reduction in time to graft vs benchmark, with strong investigator satisfaction and consistent performance across wounds.
LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AVITA Medical, Inc. , (“ AVITA " or the "Company") ( NASDAQ : RCEL ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
AVITA Medical highlights new Cohealyx data and real-world evidence at upcoming ABA 2026, advancing wound healing and improving patient recovery outcomes
Avita Medical Inc. (NASDAQ: RCEL - Get Free Report) has earned an average rating of "Hold" from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the